Epidemiology and clinical characteristics of elite controllers

Current Opinion in HIV and AIDS

Volumn 6, Issue 3, 2011, Pages 163-168

  Okulicz, Jason F ^a   Lambotte, Olivier ^b,c,d  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b INSERM   (France)

^c BICÊTRE HOSPITAL   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

elite controllers; HIV; HLA B57; vaccine; viral load

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLELE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE COURSE; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; SEROCONVERSION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HUMANS; VIREMIA;

EID: 79955467398     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328344f35e     Document Type: Article

References (43)

1. Cao Y, Qin L, Zhang L, et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995; 26:201-208.
2. Madec Y, Boufassa F, Avettand-Fenoel V, et al. Early control of HIV-1 infection in long-term nonprogressors followed since diagnosis in the ANRS SEROCO/ HEMOCO cohort. J Acquir Immune Defic Syndr 2009; 50:19-26.
3. Muñoz A, Kirby AJ, He YD, et al. Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes. J Acquir Immune Defic Syndr 1995; 8:496-505.
4. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332:209-216.
5. Sheppard HW, Lang W, Ascher MS, et al. The characterization of nonprogressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 1993; 7:1159-1166. (Pubitemid 23270961)
6. Okulicz JF, Marconi VC, Landrum ML, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis 2009; 200:1714-1723.
7. Goudsmit J, Bogaards JA, Jurriaans S, et al. Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia. AIDS 2002; 16:791-793. (Pubitemid 34274471)
8. Lefrere JJ, Morand-Joubert L, Mariotti M, et al. Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection. Blood 1997; 90: 1133-1140. (Pubitemid 27314149)
9. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996; 276:105-110.
10. Rodes B, Toro C, Paxinos E, et al. Differences in disease progression in a cohort of long-term nonprogressors after more than 16 years of HIV-1 infection. AIDS 2004; 18:1109-1116. (Pubitemid 38738510)
11. Goujard C, Chaix M, Lambotte O, et al. Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established? Clin Infect Dis 2009; 49:982-986.
12. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197:126-133. (Pubitemid 351263476)
13. Madec Y, Boufassa F, Porter K, Meyer L. Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS 2005; 19:2001-2007. (Pubitemid 41669025)
14. Lambotte O, Boufassa F, Madec Y, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005; 41:1053-1056. (Pubitemid 41368233)
15. Grabar S, Selinger-Leneman H, Abgrall S, et al. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS 2009; 23:1163-1169.
16. Walker BD. Elite control of HIV infection: implications for vaccines and treatment. Top HIV Med 2007; 15:134-136.
17. The International HIV Controllers Study. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330:1551-1557.
18. Hatano H, Delwart EL, Norris PJ, et al. Evidence for persistent low level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 2009; 83:329-335.
19. Pereyra F, Palmer S, Miura T, et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis 2009; 200:984-990.
20. Sajadi MM, Constantine NT, Mann DL, et al. Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J Acquir Immune Defic Syndr 2009; 50:403-408.
21. Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008; 197:563-571. (Pubitemid 351321534)
22. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 2000; 97:2709-2714. (Pubitemid 30159236)
23. Migueles SA, Laborico AC, Shupert WL, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3:1061-1068. (Pubitemid 35363659)
24. Blankson JN, Bailey JR, Thayil S, et al. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 2007; 81:2508-2518.
25. Bailey JR, Williams TM, Siliciano RF, Blankson JN. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med 2006; 203:1357-1369. (Pubitemid 43736603)
26. Boufassa F, Saez-Cirion A, Le Chenadec J, et al. Heterogeneous immunovirological outcomes in the 81 HIV controllers enrolled in the ANRS HIV Controllers National Program. 17th CROI, 2010, San Francisco; poster 981, abstract W-115.
27. Kiepiela P, Ngumbela K, Thobakgale C, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46-53. (Pubitemid 46067385)
28. Han Y, Lai J, Barditch-Crovo P, et al. The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors. AIDS 2008; 22:541-544. (Pubitemid 351317300)
29. Lamine A, Caumont-Sarcos A, Chaix ML, et al. Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS 2007; 21:1043-1045. (Pubitemid 46684337)
30. Sajadi MM, Heredia A, Le N, et al. HIV-1 natural viral suppressors: control of viral replication in the absence of therapy. AIDS 2007; 21:517-519.
31. Emu B, Sinclair E, Favre D, et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005; 79:14169-14178. (Pubitemid 41552715)
32. Lambotte O, Ferrari G, Moog C, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009; 23:897-906.
33. Sáez-Cirión A, Sinet M, Shin SY, et al. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol 2009; 182:7828-7837.
34. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107:4781-4789. (Pubitemid 43882629)
35. Sáez-Cirión A, Lacabaratz C, Lambotte O, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007; 104:6776-6781. (Pubitemid 47175577)
36. Hersperger AR, Pereyra F, Nason M, et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog 2010; 6:e1000917.
37. Bailey JR, Zhang H, Wegweiser BW, et al. Evolution of HIV-1 in an HLAB*57-positive patient during virologic escape. J Infect Dis 2007; 196:50-55. (Pubitemid 46982737)
38. Casado C, Pernas M, Alvaro T, et al. Coinfection and superinfection in patients with long-term, nonprogressive HIV-1 disease. J Infect Dis 2007; 196:895-899. (Pubitemid 47378940)
39. Clerc O, Colombo S, Yerly S, et al. HIV-1 elite controllers: beware of superinfections. J Clin Virol 2010; 47:376-378.
40. Rachinger A, Navis M, van Assen S, et al. Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection. Clin Infect Dis 2008; 47:e86-e89.
41. Sedaghat AR, Rastegar DA, O'Connell KA, et al. T cell dynamics and the response to HAART in a cohort of HIV-1-infected elite suppressors. Clin Infect Dis 2009; 49:1763-1766.
42. Okulicz JF, Grandits GA, Weintrob AC, et al. CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy. Clin Infect Dis 2010; 50:1187-1191.
43. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321-333.